PREreviews de Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans

Saltar a detalles del preprint Saltar a PREreviews

Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans

por Shuvechha Chakraborty, Ameya Pawaskar, Siddhanath Metkari, Taruna Madan y Susan Idicula-Thomas

Publicado: 12 de marzo de 2025
Servidor: bioRxiv
DOI: 10.1101/2025.03.12.642842

Resumen

Emergence of life-threatening fungal infections like systemic candidiasis concurrently with bacterial infections and limitations of current antifungal therapies warrants the discovery of novel inhibitors. We identified besifloxacin (BS), an FDA-approved antibacterial, as a potent antifungal inhibitor. A combination of besifloxacin with fluconazole showed a positive synergy (δ = 29.58) resulting in 80% inhibition of microbial growth. BS was able to reduce the MIC of FLC from 2mg/L to 0.5 mg/L when used in combination. Additionally in murine systemic Candida infection, BS reduced fungal load by 83% in mice kidneys at a dose of 100 mg/kg/day. The findings demonstrated the antifungal potential of BS, proposing its use in combination therapy with fluconazole to combat resistance through alternative mechanisms.

Leer el preprint

1 PREreview

Redactar una PREreview Solicitar una PREreview

PREreview de Grace Toolsie Toolsie y colaboradores/as

Escrito por Grace Toolsie Toolsie y Brenda Ametepe
Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans
1. Summary and Overall Impression
  …
Leer la PREreview de Grace Toolsie Toolsie y colaboradores/as